The U.S. Patent and Trademark Office (USPTO) has changed its rules governing continuing applications and Requests for Continued Examination (RCE). According to the USPTO, the changes will allow it to conduct a better and more thorough and reliable examination of patent applications. The new rules should prompt patent applicants to examine their portfolios and determine whether they should take any action before the new rules take effect on November 1, 2007.
The new rules will not have any effect on the applicant’s ability to file continuing applications before they take effect. On or after November 1, the new rules will limit applicants to two continuing applications (e.g., continuations or continuations-in-part) and a single RCE in any one application family. Applicants seeking to file additional applications exceeding these limits must petition the USPTO and show that the additional application or RCE is justified.
These new limits are a significant departure from the USPTO’s prior rules governing continuing applications and RCEs. However, the USPTO has adopted policies for the transition that will provide applicants some reprieve. The USPTO’s “one more” policy will allow applicants to file an additional continuing application, even after November 1, without requiring a petition and showing, so long as the initial application was filed prior to August 21, 2007. Any continuations or continuations-in-part filed between August 21 and November 1 will exhaust the “one more” application allowance.
The figure below illustrates the application of this policy. The initial application (I) and two continuations (C) were filed prior to August 21, 2007. The applicant is therefore permitted “one more” continuation or continuation-in-part without petition. In this example, the “one more” application was filed prior to November 1, 2007, but note that it may have been filed after that date without a petition and showing. As a result of filing the additional application, the applicant exhausted the “one more” application allowance. Any subsequent continuation application (P) requires the appropriate petition and showing.
If you have any questions about the USPTO’s rules, or their effect on your patent portfolio, please contact the Intellectual Property Group at Benesch Friedlander Coplan & Aronoff LLP.
Latest News
HHS OIG Sends a Strong Warning to State Medicaid Fraud Control Units: Signals Aggressive Federal Oversight of State Medicaid Fraud Enforcement
On May 13, 2026, the U.S. Department of Health and Human Services Office of Inspector General (“HHS OIG”) sent a letter to the Attorneys General of every state warning that the federal government will impose strict compliance requirements on the state’s Medicaid Fraud Control Unit (“MFCU”).
CMS Imposes Nationwide Moratorium on Home Health Agency and Hospice Enrollments
The Securities and Exchange Commission (“SEC”) remains active on both investigative and litigation fronts. Associate Director Lee emphasized that investor protection continues to be the agency’s central mandate, with enforcement efforts concentrated on misrepresentation and disclosure failures, market manipulation, insider trading and fraud using artificial intelligence.
Word on the Street: Insights from Federal Enforcement Leaders in the Northern District of California
The Securities and Exchange Commission (“SEC”) remains active on both investigative and litigation fronts. Associate Director Lee emphasized that investor protection continues to be the agency’s central mandate, with enforcement efforts concentrated on misrepresentation and disclosure failures, market manipulation, insider trading and fraud using artificial intelligence.
DOJ Strikes Again: Healthcare Fraud Enforcement Escalates as DOJ Deploys West Coast Strike Force
On April 30, 2026, the U.S. Department of Justice (“DOJ”) announced the creation of the West Coast Health Care Fraud Strike Force (the “Strike Force”), a new multidistrict enforcement initiative targeting healthcare fraud schemes across Arizona, Nevada, and Northern California.